FILTER
FILTERED INTERVIEW RESULTS
Trevor P. Castor
PRESIDENT & CEO, APHIOS CORPORATION
"In 2021, we focused on introducing our green pathogen reduction technology to biotechnology and pharmaceutical companies."
Jeff Butler
PRESIDENT, AMPAC FINE CHEMICALS, AN SK PHARMTECO COMPANY
"Outside of our manufacturing capabilities, AFC is investing and featuring AMPAC Analytical given the growing demand for pharmaceutical testing services."
Louis Kassa
PRESIDENT & CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"Our blueprint to success has manifested in six IPOs and over US$3 billion worth of company value created."
Jan Kengelbach
CEO, AENOVA GROUP
"While it's always easier to deny a certain service if you don't yet have the technical expertise in a particular area, in the long-term it is advantageous to explore the possibility of investing in that area with the customer."
Russell Trenary
PRESIDENT & CEO, OUTLOOK THERAPEUTICS
"If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."
Albert Friesen
CEO & CHAIRMAN OF THE BOARD, MEDICURE INC.
"Our recently launched e-commerce site for Marley Drug has huge potential and will be our most significant driver of growth and major source of our profits moving forward."
Olga Potapova
FOUNDER, CEO & SCIENTIFIC DIRECTOR, CURELINE
Cureline updates GBR on its global activities.
Jennifer Cannon
SVP GLOBAL HEAD OF MAMMALIAN BIOLOGICS, LONZA
"Our fixed-price, fastest DNA-to-IND program is packaged in a standardized platform to allow clients to bring a new antibody molecule to IND filing in a rapid amount of time."
Mark Egerton
CEO, QUOTIENT SCIENCES
"The focus of our integrated Translational Pharmaceutics programs is to provide the customer with a development platform capable of responding in real-time to emerging development data and maintain an overall timeline to proof of concept."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
